Ozurdex, Iluvien, and Yutiq: How Retina Specialists Choose Between Steroid Implants
Steroid Implants for the Retina at a Glance
Most eyes settle down quietly in the first week. The signs below are uncommon. If one appears, call your eye doctor the same day. If the office is closed, go to an emergency room.
- Severe eye pain that is new, or pain that keeps building.
- Decreased vision, or a dark patch that grows.
- A red eye with light sensitivity.
- A shower of new floaters, or flashing lights.
- Eye ache with halos around lights, or with nausea.
Infection inside the eye (clinical: endophthalmitis) is rare. One large United States review of eye injections found about 6 cases in every 10,000 of them.1 Rare is not the same as wait. The label tells patients to seek advice if the eye turns red, painful, or sensitive to light, or if vision changes.2 Treated in hours, these problems are much easier to control. So make the call the same day.
All three are tiny drug pellets placed inside the eye through a needle, in the office. Each releases a steroid slowly to quiet the swelling that blurs central vision. They differ in how long they last, what they are approved to treat, and how much cataract and pressure risk that length brings.
Ozurdex carries dexamethasone in a polymer that dissolves and gives roughly 3 to 6 months of effect, while Iluvien and Yutiq carry fluocinolone acetonide in a tube that does not dissolve and releases drug for roughly 36 months.3 Ozurdex is the only one labeled for swelling after a retinal vein blockage, and Yutiq is labeled only for long-running inflammation inside the eye.245
A retina specialist (an eye surgeon with extra training in the back of the eye) usually raises implants after something else has been tried. They are rarely the opening move.
For swelling in the center of the retina caused by diabetes, anti-VEGF injections have taken over from laser as first-line treatment, and a systematic review in the Academy's diabetic retinopathy guideline found low to moderate certainty evidence of no meaningful difference in vision between steroid and anti-VEGF treatment, with less retinal thickening but more pressure problems on steroids.6
What Each Implant Is and How It Works
Ozurdex is a small rod of dexamethasone in a polymer the eye slowly breaks down, so nothing is left behind.
Its label covers swelling in the center of the retina (clinical: macular edema) after a branch or central retinal vein blockage, non-infectious inflammation in the back of the eye (clinical: uveitis), and macular edema from diabetes.2 In the vein blockage trials, a three-line vision gain appeared within the first two months in roughly 20 to 30 of every 100 patients.2 Repeat implants are part of the plan.
Iluvien is a hair-thin tube holding fluocinolone acetonide. The tube does not dissolve, so it stays in the eye after the drug is spent.
It releases fluocinolone acetonide at a starting rate of 0.25 micrograms a day and is designed to last 36 months.4 Its label covers diabetic macular edema in people who have already had a course of steroids without a clinically significant rise in eye pressure, plus chronic non-infectious uveitis of the back of the eye.4 That first phrase is a screening rule, and it shapes who gets offered this implant.
Yutiq is the same fluocinolone acetonide idea in a slightly smaller dose, and the narrowest of the three on paper.
Yutiq releases fluocinolone acetonide at a starting rate of 0.25 micrograms a day for 36 months, and it is labeled only for chronic non-infectious uveitis affecting the back of the eye.5 In its two randomized trials, inflammation came back within 6 months in 16 of 87 and 22 of 101 treated eyes, against 33 of 42 and 28 of 52 sham eyes.5
The polymer is not a detail. It decides how reversible your decision is.
The dexamethasone implant uses a biodegradable polymer, while both fluocinolone implants sit in a non-biodegradable polyimide tube that stays in the eye.3 With a dissolving implant, a bad steroid reaction fades as the drug runs out. With a three-year implant, the same reaction has to be managed with drops, and sometimes surgery, for as long as the drug keeps releasing.
Ozurdex, Iluvien, and Yutiq Side by Side
Here is the plain comparison.
| Implant | Steroid and dose | Designed duration |
|---|---|---|
| Ozurdex | Dexamethasone 0.7 mg. | About 3 to 6 months. |
| Iluvien | Fluocinolone 0.19 mg. | About 36 months. |
| Yutiq | Fluocinolone 0.18 mg. | About 36 months. |
The doses come from each label, and the durations reflect the release profiles described for the dexamethasone and fluocinolone implants.2453
The labeled diagnosis is usually the first filter, because it also drives insurance approval.
| Implant | Conditions listed on its label |
|---|---|
| Ozurdex | Vein blockage swelling. Uveitis. Diabetic swelling. |
| Iluvien | Diabetic swelling after a prior steroid course. Uveitis. |
| Yutiq | Uveitis only. |
Only Ozurdex carries a labeled use for macular edema after a retinal vein blockage.245
This is the difference most patients feel in daily life.
| Implant | Repeat pattern in the pivotal trials |
|---|---|
| Ozurdex | No sooner than 6 months apart. About four over 3 years. |
| Iluvien | About 75 of every 100 patients needed only one. |
| Yutiq | Studied as a single implant, with usual care after. |
In the diabetic trials, dexamethasone implant retreatment was allowed no sooner than 6 months apart and patients averaged about four implants over 36 months, while about 75 of every 100 patients in the fluocinolone trials received only one insert across the same 3 years.784
These are patterns, not rules. Your eye and your history override every pattern here.
A dissolving implant tends to suit a first steroid trial, an eye that still has its natural lens, an unknown pressure history, and swelling after a vein blockage. A three-year implant tends to suit disease that keeps returning, an eye that has already tolerated steroid without a pressure jump, and a person for whom frequent visits are hard. Dexamethasone implants are described as a reliable mid-term option, particularly in eyes that already have a lens implant from cataract surgery.3
How Retina Specialists Actually Decide
The diagnosis removes options from the table first.
If your swelling follows a retinal vein blockage, the dexamethasone implant is the one with that use on its label.2 If you have chronic non-infectious uveitis, all three carry a labeled use. If you have diabetic macular edema, two do. Yutiq's label is limited to chronic non-infectious uveitis of the back of the eye, so it does not enter a diabetes-only conversation.5
If you have already had cataract surgery, the largest downside of steroid implants is behind you.
In the diabetic trials, cataract developed in 166 of 243 natural-lens eyes given the dexamethasone implant, against 49 of 230 sham eyes.2 With the three-year fluocinolone implant, cataract developed in 192 of 235 natural-lens eyes against 61 of 121 sham eyes, and about 80 of every 100 of those patients went on to cataract surgery, against about 27 of every 100 on sham.4 Cataract surgery is a routine, well established operation, so this is a trade-off to plan for rather than a reason to refuse treatment. Many specialists still lean toward the shorter implant in an eye with a clear lens.
Some people's eye pressure (clinical: intraocular pressure) climbs sharply on steroids. This is hard to predict in advance, so specialists test rather than guess.
That is why a short-acting steroid, or a dissolving implant, often comes first. If pressure holds steady, a long-acting implant becomes a safer proposition. The Iluvien label builds this sequence into the indication itself, limiting its diabetic use to people who have already had a steroid course without a clinically significant rise in eye pressure.4
Each label carries its own hard stops, and they are not identical.
- Ozurdex is contraindicated in active or suspected eye or eyelid infection, in glaucoma with a cup to disc ratio above 0.8, and when the back capsule of the lens is torn or ruptured, because the implant can move to the front of the eye.2
- Iluvien is contraindicated in active or suspected eye or eyelid infection and in glaucoma with a cup to disc ratio above 0.8.4
- Yutiq lists eye or eyelid infection and known hypersensitivity to its components as contraindications.5
If one of these applies to you, it usually shifts the plan rather than ending it. Ask which alternative your specialist would use instead.
Risks, Side Effects, and a Realistic Outlook
If you still have your natural lens, expect it to cloud faster than it otherwise would.
In the uveitis trials of the 0.18 mg fluocinolone implant, cataract was recorded in 63 of 113 natural-lens eyes, against 13 of 56 sham eyes.5 The Ozurdex label counsels patients that a cataract may follow repeated treatment, that vision will decrease if it does, and that an operation is then needed to remove it.2 A clouded lens can be replaced later, so the usual path is to treat the retina now and handle the lens afterward.
Steroid inside the eye can push pressure up, and the longer the steroid stays, the longer that risk runs.
With the dexamethasone implant in diabetic macular edema, 136 of 324 patients needed pressure-lowering medication and 4 of 324 needed surgery for pressure.2 With the three-year fluocinolone implant, 144 of 375 patients needed pressure-lowering medication and 18 of 375 needed a pressure operation.4 In the uveitis trials of the 0.18 mg implant, 98 of 226 eyes needed pressure-lowering medication and 5 of 226 needed pressure surgery.5 Most rises are handled with drops and are found at routine checks, which is the practical reason those appointments matter.
The injection itself carries a small set of risks shared by all three implants.
Labels for these implants warn that intravitreal injections have been linked to infection inside the eye, inflammation, raised eye pressure, and retinal detachment, and that patients should be monitored afterward.24 A United States insurance claims analysis of anti-VEGF eye injections recorded 498 infections across 818,558 injections, about 6 in every 10,000.1 These are treatable when caught early, and catching them early depends on you calling the same day the warning signs above appear.
These are group averages, not a forecast for your eye.
In the 3-year dexamethasone implant trials for diabetic macular edema, 34 of 163 and 30 of 165 treated patients gained 15 or more letters of vision, against 19 of 165 and 16 of 163 on sham.72 In the fluocinolone insert trials, 51 of 190 and 57 of 186 treated eyes gained 15 or more letters by month 24, against 14 of 95 and 16 of 90 sham eyes.84 For uveitis, a single dexamethasone implant cleared vitreous haze at week 8 in about 47 of every 100 treated eyes, against about 12 of every 100 sham eyes.92 A Cochrane review cited in the Academy's guideline concluded that steroids inside the eye may improve vision in diabetic macular edema, but modestly, by about one line or less.6
Cost, Coverage, and Getting the Implant Approved
You will not pick these up at a pharmacy. They are generally supplied to the practice, given in the office, and billed to your medical benefit rather than your drug benefit.
Your share therefore depends on your medical deductible and coinsurance, not a pharmacy tier. Ask the billing staff for a written estimate before the day of the injection, covering both the drug and the procedure.
Insurers generally approve these against the labeled diagnosis, so the paperwork follows your specialist's logic.
One health plan's published policy runs all three implants through prior authorization, ties approval to the labeled diagnosis and to an ophthalmologist prescriber, and states that other uses are considered investigational and not covered.10 Rules vary between plans, so treat that as an example rather than a guarantee. If a request is declined, ask whether an appeal with your scans and treatment history is worth filing.
When to Call Your Eye Doctor After a Steroid Implant
Some grittiness, a red patch on the white of the eye, and a few new floaters are common after any intravitreal injection and usually settle on their own.
Floaters were the second most frequently reported eye complaint in the fluocinolone implant trials, recorded in 80 of 375 treated patients against 17 of 185 on sham.4 A dexamethasone implant can also show up as a small dark line in your vision while it dissolves. What is not normal is pain that builds, vision that drops, or light that becomes hard to tolerate.
Later problems tend to arrive quietly, which is exactly why they get missed.
Gradual dimming or glare over months usually points to cataract, and that is fixable. A steady, painless pressure rise often has no symptoms at all, which is why scheduled checks are the real safety net. Tell your doctor promptly if your swelling symptoms return, since new distortion or central blur can mean the implant's effect is fading.
Ask for your schedule in writing at the first visit.
Both the dexamethasone and fluocinolone labels direct that patients be monitored for raised eye pressure and for infection inside the eye after the injection.24 Expect a pressure check within the first weeks, then at intervals for as long as the steroid is releasing, which for a three-year implant means years of checks. If you cannot make a visit, call and move it rather than skipping it.
Questions Patients Ask Before Choosing an Implant
No. The implants are tiny and sit in the gel toward the back of the eye, well away from the surface. Some people briefly see a dexamethasone implant as a faint dark line at the edge of vision while it dissolves, and that fades. Any soreness in the first day or two comes from the injection site on the surface of the eye rather than from the implant. Pain that grows rather than settles is a reason to call the same day.
Removal is not the usual answer. The dexamethasone implant uses a polymer that biodegrades, so it disappears on its own, while both fluocinolone implants sit in a tube that does not biodegrade and stays in the eye.3 The Ozurdex label counsels that a rise in eye pressure will be managed with eye drops and, rarely, with surgery.2 That is the usual route with a long-acting implant too, which is why the pressure question is settled before one goes in.
Because a steroid reaction you cannot switch off is harder to manage than one that fades. If your eye pressure climbs on a three-year implant, you may need drops, and sometimes surgery, for as long as it keeps releasing. The Iluvien label reflects this caution directly, restricting its diabetic use to patients who have already had a steroid course without a clinically significant pressure rise.4 Starting shorter is a way of learning how your eye handles steroid first.
All three can raise pressure, and the shorter one gives you a shorter exposure. Reported rates come from different diseases and trial designs, so they cannot be compared head to head. Pressure surgery was needed in 4 of 324 patients on the dexamethasone implant, 18 of 375 on the three-year fluocinolone implant for diabetes, and 5 of 226 eyes on the 0.18 mg implant for uveitis.245 Your own pressure history matters more than any of these figures.
More Questions About Living With a Steroid Implant
Sooner than most people expect, though not on day one. In the vein blockage trials of the dexamethasone implant, gains of three lines of vision appeared within the first two months in roughly 20 to 30 of every 100 patients, and that effect lasted about one to three months after it began.2 Long-acting implants build more slowly and are judged over months. Your scan often improves before your reading vision does, so an unchanged eye chart at two weeks is not failure.
It depends on which implant you received. The dexamethasone implant's polymer biodegrades in the eye, while the fluocinolone implants use a non-biodegradable polyimide tube that remains in the eye.3 An empty fluocinolone tube is generally left in place rather than removed. Tell your doctor if anything in your vision bothers you, so it can be checked rather than assumed.
That is a common and expected scenario, not a failure of the decision. Your specialist can add anti-VEGF injections, treat with laser in selected cases, or plan the next implant. In the diabetic trials, dexamethasone implant retreatment was allowed no sooner than 6 months apart, which is why a gap is sometimes bridged with a different treatment.7 Moving from a short implant to a long one is also possible once your pressure response is known, though the reverse move is harder. Report returning distortion or blur promptly rather than waiting for your next visit.
Yes, when both eyes need treatment, though many specialists stagger the two rather than treating both on one day. Staggering keeps one eye seeing normally while the other settles, and it lets your doctor see how your pressure responds first. Each applicator treats a single eye, and the label directs a fresh applicator and a fresh sterile field for the other eye.2 Ask how your practice handles second-eye timing.
Bring these to the visit where the decision is made.
- Which implant do you recommend for my diagnosis, and what is your second choice?
- Have I ever had a pressure rise on steroids, and how would we find out?
- Do I still have my natural lens, and how does that change your advice?
- How many visits will this commit me to, and over how long?
- What is the plan if my swelling does not improve, or returns early?
- Which number do I call after hours, and what should trigger that call?
- What will this cost me under my plan, and has it been authorized yet?
- Clinical Ophthalmology (2018). Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis.
- US Food and Drug Administration label, via DailyMed (2026). OZURDEX (dexamethasone intravitreal implant) full prescribing information.
- American Academy of Ophthalmology EyeWiki. Intravitreal Steroid Injections and Implants.
- US Food and Drug Administration label, via DailyMed (2026). ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg full prescribing information.
- US Food and Drug Administration label, via DailyMed (2026). YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg full prescribing information.
- American Academy of Ophthalmology (2025). Diabetic Retinopathy Preferred Practice Pattern (2025).
- Ophthalmology (MEAD study) (2014). Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.
- Ophthalmology (FAME studies) (2012). Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
- Archives of Ophthalmology (HURON study) (2011). Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.
- Maryland Physicians Care health plan policy (2021). Intravitreal Corticosteroid Implants: Ozurdex, Iluvien, and Yutiq (prior authorization policy RX.PA.018).